XPC-7224 is a potent, selective NaV1.6 inhibitor with IC50 of 78 nM and 130 nM for human and mouse NaV1.6, respectively, interacts with the inactivated state of the channel.

XPC-5462 is a potent, selective dual inhibitor of NaV1.6 and NaV1.2 with IC50 of 10.9 nM and 10.3 nM, respectively.

UTX-143 is a potent, selective sodium-hydrogen exchange subtype 5 (NHE5) inhibitor with IC50 of 3.11 uM, 80-fold selective over NHE1.

DS43260857 is a potent, selective NaV1.7 inhibitor with IC50 of 15 nM (hNaV1.7), shows 440-fold and 930-fold selectivity over hNaV1.1 and hNaV1.5, respectively.

BW-031 iodide is a potent cationic sodium channel inhibitor, inhibited Nav 1.7 (IC50=9.5 uM) and Nav 1.1 channels with approximately sixfold greater potency than QX-314.

BW-031 chloride is a potent cationic sodium channel inhibitor, inhibited Nav 1.7 (IC50=9.5 uM) and Nav 1.1 channels with approximately sixfold greater potency than QX-314.

Benzocaine is a local anesthetic.

Aneratrigine is a sodium channel protein type 9 subunit alpha blocker.

ZVS-08 is a selective inhibitor of the voltage-gated potassium channel KV10.1 with IC50 of 3.7 uM.

VU0935685 is a potent, selective inhibitor of SLACK potassium channels with IC50 of 0.32 uM in in whole-cell, voltage-clamp electrophysiology (EP) assays, demonstrates selectivity versus hERG.

VU0542270 is the first selective inhibitor of vascular Kir6.1/SUR2B KATP channel with IC50 of 129 nM, >300-fold selective over other members of the Kir channel family.

TTQC-1 is a potent activator of the large-conductance Ca2+-activated K+ channel (BKCa channel), directly and reversibly activates the macroscopic current of BKCa channels expressed in Xenopus oocytes from both sides of the cellular membrane, increases the

Tamapin TFA salt is a venom peptide from the Indian red scorpion (Mesobuthus tamulus), potent and selective inhibitor of small conductance calcium-activated potassium channel 2 (SK2, KCNN2) with IC50 of 24 pM.

SCR2682 is a potent, selective neuronal voltage-gated potassium Kv7/KCNQ/M channel opener (activator) with EC50 of 9.8 nM (Kv7.2/Kv7.3), 100-fold more potency than retigabine.

NPBA-4 is a potent selective TWIK2 channel inhibitor with IC50 of 8.41 uM. shows little to no effects on TWIK1 channel.

NPBA is a potent, selective pharmacological activator for K2P channel TASK-3 with EC50 of 6.7 uM (TASK-3 whole-cell currents), shows good selectivity between TASK channels.

NIP-142 (NIP142) is an anti-arrhythmic agent by targeting cardiac K+ channel Kv1.5 (Kv1.5) currents, inhibits the steady-state phase with IC50 of 4.75 uM.

ML308 (ML 308) is a potent, selective inhibitor of two-pore domain potassium channel KCNK9 (TASK-3, K2P9.1) with IC50 of 130 nM in thallium influx fluorescent assays and 413 nM in automated electrophysiology assays, respectively.

LAKI (Light Activated K+ channel Inhibitor) is a specific photoswitchable inhibitor of the pain-related two-pore-domain potassium (K2P) TREK and TRESK channels.

C101248 is the first selective small-molecule inhibitor of tandem pore domain halothane-inhibited K+ channel 1 (THIK-1) with IC50 of 50 nM for both mouse and human THIK-1.

BK channel modulator BC5 is an allosteric modulator of BK type Ca2+-activated K+ channels, interacts with the CTD-VSD interface and specifically modulates the Ca2+ dependent activation mechanism.

AUT00201 is a potent, selective Kv3 potassium channel modulator with potential for the treatment of rare epilepsy syndromes.

ACOU085 (ACOU 085) is a potent small-molecule agonist of Kv7.4 (KCNQ4) channel with higher potency than ML-213 in the nanomolar range.

ACOU001 (ACOU 001) is a potent small-molecule agonist of Kv7.4 (KCNQ4) channel with potential effect against ge-related hearing loss (ARHL) and other hearing impairments related to compromised KV7.4 function.

Filapixant (BAY1902607) is a potent, selective P2X3 receptor antagonist, shows a substantially higher in vitro selectivity for P2X3 over P2X2 when compared with Eliapixant (BAY1817080, Cat# PC-72754).

DT-0111 (DT0111) is a selective and effective, water-soluble antagonist at P2X2/3R, does not activate or block P2YR, inhibits ATP-induced current in nodose ganglionic cells with IC50 of 0.3 uM.

RGH-560 (RGH560) is a potent, selective α7 nAChR positive allosteric modulator (PAM) with EC50 of 190 nM (Ca2+-influx).

MK4334 is a potent, selective positive allosteric modulator (PAM) of the α7 nAChR with potential for treatment of Alzheimer's disease.

JWX-A0108 is a novel selective type I α7 nAChR positive allosteric modulator (PAM) with EC50 of 4.35 uM, shows no potentiation effect on α3β4 nAChR, α4β2 nAChR, or 5-HT3AR.

DM506 is a novel ibogamine derivative and inhibitor of α7 and α9α10 nicotinic acetylcholine receptors (nAChRs) with IC50 of 5.1 uM, 5.6 uM and 6.4 uM for α9α10, α7β2 and α7nAChR, respectively.